ARCHIVES

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

This article is from The Cancer Letter archive.

Vol. 30 No. 40 | October 22, 2004

Download PDF Visit The Full Archive

Related Articles

NCI Closes Iressa Trial For NSCLC When Data Indicate No Survival Benefit

April 29, 2005

In Congress: $135 Million Expected For DOD Breast Cancer Research Program

July 24, 1998

Lombardi Cancer Center, UDC Collaborate to Increase Cancer Awareness Among Blacks

August 3, 2001

In Congress: Senate Committee Provides Increase To DOD Program

August 1, 1997

White House To Appoint Richard Klausner, Molecular Biologist, As NCI’s 11th Director

July 28, 1995

NCI Chief Operating Officer Lawrence Ray To Retire

April 24, 2009